Sector
988 stories · page 32 of 50
"The potential tuck-in acquisition of NCC's operating assets will continue to expand the number of patients across Canada that have access to our products and services," said Ken Yoon, CEO of Pathway Health
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
"This brings us one step closer to achieving our goal of a Canadian wide network of purpose-built programs for veterans and first responders who desperately need access to care," said Wellbeing interim CEO Adam Deffett
For the three-month period ending December 31, 2021, the company recorded revenue of $324,902, reflecting a 13.3% increase from the year-ago quarter thanks to sales of ketamine-infusion treatments
“The company has always wanted to make a positive and significant impact on mental health and this brings us one step closer,” Wellbeing interim CEO Adam Deffett said
The company said it had also added a second fluoroscopy suite at Silver that will allow the company’s pain specialists to treat more patients using “real-time diagnostic imaging, allowing for more precise treatments”
Roquefort bought LYRAMID in December LYRAMID business is a pioneer in midkine inhibition When overexpressed, midkine is linked with a host of diseases
CEO Irwin noted that the company sees itself as gaining the national brand first-mover advantage and will be leveraging its brand equity and status as a cult brand to expand rapidly as society embraces the psychedelic mental health revoluti
The results of the study come from 13 countries, eight enterprise markets and 529 participants and "demonstrate a substantial and clinically meaningful improvement in nightly sleep duration achieved by 59% of employee participants", the com
KGK is currently working on psychedelic drug projects with eight distinct clients, managing four clinical trials including a Phase 1 study of a proprietary psilocybin extract in healthy adults
Braxia Scientific's researchers have published 43 ketamine-related manuscripts in peer-reviewed biomedical journals, and its wholly-owned subsidiary has established a growing database with key clinical outcomes for an ongoing clinical trial
Both companies plan to jointly submit a clinical trial application to Health Canada for a Phase 2A clinical study evaluating psilocybin microdose therapy for fragile X syndrome
The government is looking for the best way to roll out the pill in a largely vaccinated population
“Wellbeing Digital Sciences is a name that acknowledges each one of our three core pillars: clinic-based treatments, contract research, and health technology,” said Adam Deffett, interim CEO of Wellbeing
The firm is embarking on its first clinical study evaluating psilocybin in the treatment of methamphetamine use disorder and advancing the development of an oral psilocybin thin file strip and psilocybin microneedle patch
“This exclusive agreement with VW is a meaningful opportunity to help even more veterans and other members of the general public who are battling daily with anxiety, depression and PTSD,” said Ketamine One chief operating offer Steven Ingle
The company is currently working with its contract research organization (CRO) partners to finalize the study's design ahead of an expected pre-clinical trial application with Health Canada
The company’s common shares will begin trading on the OTCQB under the symbol KONEF as of the opening of the market today, January 12, 2022
"While use of additional boosters can be part of contingency plans, repeated vaccinations within short intervals would not represent a sustainable long-term strategy," said EMA official Marco Cavaleri
